Breast cancer incidence has steadily increased in the past decades internationally. Now, one in eight Australian women will be diagnosed with breast cancer in their lifetime. Although survival has improved dramatically, breast cancer remains the number one cause of cancer disease burden around the world. Prevention potentially offers the most cost-effective strategy for cancer control, and would reduce the social impact of breast cancer.
Dr Cui's areas of interest are cancer and pregnancy, understanding and preventing the unwanted effects of cancer treatments on ovarian function and fertility, and cancer prevention. Her research focuses on oncofertility and cancer prevention. She is the first author of the ASCO research statement regarding assessing ovarian toxicity in cancer clinical trials. She is a member of the prevention working group of the Lancet Breast Cancer Commission and is the Breast Cancer Trials Australia deputy chair for the Decrescendo trial.
